Submission to Canada’s Drug Agency (CDA) on Breztri Aerosphere for Asthma

Welcome and Explanation of Patient Input Submissions

Asthma Canada Patient Survey:
Breztri Aerosphere (budesonide/glycopyrronium/formoterol)

Patients and caregivers are invited to share their experiences to help inform Canada's drug review and funding decisions. Asthma Canada is preparing a patient submission to Canada's Drug Agency (CDA) as part of the reimbursement review for Breztri Aerosphere (budesonide/glycopyrronium/formoterol), a twice-daily maintenance inhaler for asthma in adults and adolescents aged 12 and older whose symptoms are not adequately controlled with a combination inhaled corticosteroid (ICS) and long-acting beta agonist (LABA).

Breztri adds a third medication class (a long-acting muscarinic antagonist - LAMA) to help open the airways further. It is not a rescue inhaler, as patients on Breztri still use a separate rescue inhaler as needed.

Your input will help describe the impact of asthma, experiences with current treatments, and what matters most to patients and caregivers.

The survey will take approximately 10-12 minutes to complete.

Please complete the survey by August 7, 2026.